Abstract: A method for promoting healing by administration of an inhibitor of the activity of retinoic acid is provided. Preferred compounds for use in such treatment include antagonists of retinoic acid. The method is particularly applicable for promoting skin healing and treatment of surgical and traumatic wounds.
Type:
Grant
Filed:
July 28, 1998
Date of Patent:
October 26, 1999
Assignee:
Centre International de Recherches Dermatologiques Galderma
Inventors:
Michel Demarchez, Patricia Rossio, Andre Jomard
Abstract: Pharmaceutically/cosmetically-active adamantyl-substituted retinoid compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formula (a) - (d): ##STR2## and are useful for the treatment of disorders and/or ailments manifesting an overregulation of RAR receptors and/or a hypervitaminosis A.
Type:
Grant
Filed:
May 3, 1996
Date of Patent:
September 14, 1999
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: Nongreasy, nonsticky cosmetic and/or dermatological compositions for topical application to human skin and/or hair, characteristically without imparting a shiny appearance thereto, contain at least one fatty substance and an amount of deformable hollow particulates effective to avoid the greasy and/or sticky feel otherwise attributable to the at least one fatty substance, said deformable hollow particulates comprising a copolymer of vinylidene chloride, acrylonitrile and a (meth)acrylic comonomer and having a particle size ranging from 1 .mu.m to 250 .mu.m.
Type:
Grant
Filed:
June 9, 1997
Date of Patent:
August 17, 1999
Assignee:
Centre International de Recherches Dermatologiques Galderma
Inventors:
Josiane Allec, Eve Ferrara, Isabelle Bara
Abstract: Novel pharmaceutically/cosmetically-active biaromatic amido compounds have the structural formula (I): ##STR1## in which Ar is a radical selected from among those of the following formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
February 23, 1996
Date of Patent:
August 10, 1999
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active polycyclic polyenic compounds have the structural formula (I): ##STR1## and are useful for modulating cellular hormone receptors.
Type:
Grant
Filed:
September 2, 1997
Date of Patent:
June 8, 1999
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active heterocyclic biaryl compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(h): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for cosmetic applications and for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
June 30, 1997
Date of Patent:
May 18, 1999
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: The present invention relates to new aromatic compounds, to their preparation and to their use in human and veterinary medicine and in cosmetic compositions.
Type:
Grant
Filed:
September 26, 1994
Date of Patent:
February 9, 1999
Assignee:
Centre International De Recherches Dermatologiques Galderma (CIRD Galderma)
Abstract: Topically applicable cosmetic/dermatological compositions well suited for the therapeutic treatment or care of human skin, nails, hair and/or of the scalp, in particular for treating and/or preventing xerosis, ichthyosis, actinic keratosis and/or photoinduced cutaneous aging, comprise a water-in-oil emulsion containing (a) at least 10% by weight of at least one hydroxy acid, (b) an effective emulsifying amount of at least one polyoxyalkylenated silicone, and (c) an effective coemulsifying amount of at least one polyol alkyl ester, polyol alkyl ether or oxyalkylenated alkyl ether, with the proviso that the subject compositions are devoid of any C.sub.1 -C.sub.4 alkanol.
Type:
Grant
Filed:
December 14, 1995
Date of Patent:
January 26, 1999
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-.alpha. receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.
Type:
Grant
Filed:
January 22, 1997
Date of Patent:
December 29, 1998
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active polyaromatic heterocyclic compounds have the structural formula (I): ##STR1## in which Z is a divalent radical selected from among --O--, --S-- or --Nr'-- and Ar is either a radical having the following structural formula (II): ##STR2## or a radical having the following structural formula (III): ##STR3## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
March 14, 1996
Date of Patent:
December 15, 1998
Assignee:
Centre International De Recherches Dermatologiques Galderma
Inventors:
Bruno Charpentier, Philippe Diaz, Philippe Nedoncelle
Abstract: The invention relates to the use of metronidazole, or preferably of a combination of metronidazole and clindamycin, as active principle for the manufacture of pharmaceutical compositions, more particularly dermatological compositions, intended for an anti-inflammatory treatment by the topical route.
Type:
Grant
Filed:
March 25, 1997
Date of Patent:
December 15, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma (C.I.R.D. Galderma)
Inventors:
Janusz Czernielewski, Josiane Allec, Martine Bouclier
Abstract: The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-.alpha. receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.
Type:
Grant
Filed:
January 22, 1997
Date of Patent:
October 27, 1998
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: The present invention relates to a process for identifying RAR-antagonist molecules, characterized in that it comprises the following steps: (i) a sufficient amount of an RAR-agonist molecule is applied topically to a part of the skin of a mammal, (ii) a molecule capable of having an RAR-antagonist activity is administered systemically or topically to this same mammal, or to this same part of the skin of the mammal, before, during or after step (i), and (iii) the response on that part of the skin of the mammal thus treated is evaluated.
Type:
Grant
Filed:
June 19, 1996
Date of Patent:
October 27, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active adamantyl-substituted polycyclic acetylene compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(f): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
July 2, 1996
Date of Patent:
August 25, 1998
Assignee:
Centre International De Recherches Dermatologiques Galderma
Inventors:
Jean-Michel Bernardon, Bruno Charpentier
Abstract: Novel pharmaceutically/cosmetically-active adamantyl-substituted biaromatic compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a')-(f'): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
December 2, 1996
Date of Patent:
July 28, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
April 26, 1995
Date of Patent:
June 16, 1998
Assignee:
Centre International De Recherches Dermatologiques Galderma
Abstract: Pharmaceutical/dermatological compositions comprising (a) at least one first ligand displaying selective activity for the RXR receptors and (b) at least one second ligand displaying selective activity for the RAR-.alpha. receptor, are useful for modulating the proliferation and/or differentiation of HL-60 type cells, in particular for the systemic treatment of acute promyelocytic leukemia.
Type:
Grant
Filed:
July 27, 1995
Date of Patent:
June 16, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma
Inventors:
Serge Michel, Christine Cathelineau, Marie-Cecile Lenoir-Viale, Michel Demarchez
Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
January 22, 1996
Date of Patent:
June 9, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: Novel pharmaceutically/cosmetically-active dibenzofuran compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (II) to (VI): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Type:
Grant
Filed:
October 30, 1995
Date of Patent:
May 5, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma
Abstract: Apoptosis (programmed cell death) in mammalian organisms is modulated, whether initiated or suppressed, for example for preventing and/or combating photoinduced or chronologic aging of the skin or for treating a wide variety of human afflictions, by administering thereto, for such prolonged period of time as is required to elicit the desired response, an effective apoptosis-modulating amount of at least one active species selected from among methional, malondialdehyde, or factor influencing the intracellular concentration of methional or malondialdehyde.
Type:
Grant
Filed:
December 28, 1995
Date of Patent:
April 28, 1998
Assignee:
Centre International de Recherches Dermatologiques Galderma